US5011695A - Sterilization of blood and its derivatives with vitamins - Google Patents

Sterilization of blood and its derivatives with vitamins Download PDF

Info

Publication number
US5011695A
US5011695A US07/311,483 US31148389A US5011695A US 5011695 A US5011695 A US 5011695A US 31148389 A US31148389 A US 31148389A US 5011695 A US5011695 A US 5011695A
Authority
US
United States
Prior art keywords
vitamin
treatment
sterilizing agent
plasma
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/311,483
Other languages
English (en)
Inventor
Herbert Dichtelmuller
Wolfgang Stephan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest Pharma GmbH
Original Assignee
Biotest Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest Pharma GmbH filed Critical Biotest Pharma GmbH
Assigned to BIOTEST PHARMA GMBH reassignment BIOTEST PHARMA GMBH ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: DICHTELMULLER, HERBERT, STEPHAN, WOLFGANG
Application granted granted Critical
Publication of US5011695A publication Critical patent/US5011695A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases

Definitions

  • the invention relates to a method for sterilization of blood, plasma, blood- and plasma derivatives, cell suspensions or similar with a physiologically innocuous sterilant.
  • Human blood or human plasma or derived products potentially entail the risk of transmitting viral infection.
  • human pathogenic lipid viruses such as HIV, HNANBV and HBV play a special role. For this reason, preparations derived from human blood or plasma must be virus inactivated.
  • Clotting preparations such as F VIII or F IX concentrates can be sterilized by means of heat (EP 0 037 078), but require appreciable amounts of stabilizers in order to stand such a treatment. In other methods, the preparation is heated in the lyophilized state, with additional use of organic solvents, pressure or steam in combination.
  • Chemical agents such as a combination of lipid solvents and detergents or beta-propiolactone in combination with UV irradiation (EP 0 014 333) are also used.
  • the invention is based on the task of providing a virus inactivation procedure which works under physiological conditions and with physiological substances, which is suitable for sterilization of blood/plasma or their derivatives as well as for cell suspensions.
  • a physiologically well-tolerated substance which can remain in the biological material to be sterilized is used as sterilizing agent.
  • Vitamins are natural physiological substances of which the anti-infectious, health-promoting activity is already known. Moreover, vitamins do not have to be removed from the biological material to be sterilized, since the human body relies on supply of vitamins.
  • Preferred vitamins are vitamin A, B, B 1 , B 6 , B 12 , C and E.
  • Preferred salts are the acetates, such as vitamin A- and E-acetate.
  • Sterilization is carried out in that the biological material to be sterilized is mixed with 0.01 to 1.0 weight % of a vitamin (per volume% sterilisate) and preferably 0.2%, the pH value is adjusted to 5.6 to 8.5 and incubation is carried out with stirring for up to 24 hours at 10° C. to 50° C.
  • the pH value is 7.15 and the temperature is 23° C. to 37° C., and more preferentially 23° C. or 37° C.
  • the preferred sterilization time is three to four hours.
  • a dissolution mediator can be added to improve the solubility of the vitamin.
  • a preferred solubilizer is e.g. Tween 80.
  • the method in accordance with the invention enables virus inactivation in blood, blood cells, blood plasma, blood serum, constituents of blood cells (e.g. interferons, interleukins or hemoglobins, red cell concentrates or concentrates of other cellular blood compounds as granulocytes, platelets, lymphocytes etc.) as well as plasma derivatives (e.g. plasma cryopoor plasma, coagulation factors, cryoprecipitate (e.g. factor VIII, IX, X, XIII etc.), immunoglobulines, the inhibitors ⁇ 1 antitrypsin, antithrombin III etc.).
  • constituents of blood cells e.g. interferons, interleukins or hemoglobins, red cell concentrates or concentrates of other cellular blood compounds as granulocytes, platelets, lymphocytes etc.
  • plasma derivatives e.g. plasma cryopoor plasma, coagulation factors, cryoprecipitate (e.g. factor VIII, IX, X, XIII etc.
  • the sterilizing agent i.e. the vitamin
  • the sterilizing agent can remain in the biological material to be virus inactivated but it also may easily be removed from the sterilized preparation by means of washing gelfiltration, adsorption or ultrafiltration.
  • Sendai viruses were used to demonstrate virus inactivation in accordance with the discovery.
  • Sendai viruses have been proved to be very effective in experiments as model viruses for the human pathogenic lipid viruses HBV, HNANBV and HIV.
  • Herpes virus HSV-I has been used.
  • a reference sample which was also contaminated with Sendai virus was incubated under the same conditions but without addition of the vitamin.
  • the samples were frozen immediately after incubation at -80° C.
  • the infectious titers of Sendai virus were determined on incubated eggs.
  • a titer of 10 2 .7 infectious units/ml was found.
  • infectious virus was no longer demonstrated, corresponding to an inactivation of ⁇ 2.7 log 10 .
  • Human erythrocytes washed three times with 0.9% sodium chloride, were spiked with Sendai virus (dilution 1:100). 0.25% vitamin E-acetate was added to one aliquot of the virus spiked erythrocytes and the mixture incubated at 37° C. for 3 hours. The second virus spiked aliquot was incubated without vitamin addition. In all the following examples, the control sample was treated identically. Infectious Sendai virus was titrated in embryonated eggs and antigen determined by haemagglutination assay.
  • HSV-I Herpes virus
  • Herpes virus was titrated on cell culture (Rita-cells) by plaque counting. The results are given in Table II. Tween 80 alone shows almost no virus inactivation activity. Even concentrations ten times higher than those used in the combination with vitamin E are ineffective.
  • Human plasma was spiked with Sendai virus (dilution 1:50) and one aliquot of the spiked plasma was incubated in the presence of 0.2% vitamin A acetate at 23° C. for three hours.
  • Virus titration was performed as described in Example 1. Treatment with vitamin A acetate resulted in a titer reduction of Sendai virus of >2.7 log 10 (Table III).
  • Human plasma was spiked with Sendai virus as described in Example 4 and treated with vitamin A acetate (0.5%) supplemented with Tween 80 (0.15%).
  • Human plasma was spiked with Sendai virus and treated with vitamin B 6 (0.2%). Incubation was performed at 23° C. for three hours. Titration of Sendai virus was performed as described above. Titer of infectious Sendai virus was reduced by treatment with vitamin B 6 by >2.7 log 10 (Table IV). Treatment with 0.1% vitamin B 6 resulted in an inactivation of 1.0 log 10 .
  • HSV-I Herpes virus
  • HSV-I Herpes virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • External Artificial Organs (AREA)
  • Fertilizers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US07/311,483 1988-02-22 1989-02-16 Sterilization of blood and its derivatives with vitamins Expired - Fee Related US5011695A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3805459 1988-02-22
DE3805459A DE3805459A1 (de) 1988-02-22 1988-02-22 Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl.

Publications (1)

Publication Number Publication Date
US5011695A true US5011695A (en) 1991-04-30

Family

ID=6347890

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/311,483 Expired - Fee Related US5011695A (en) 1988-02-22 1989-02-16 Sterilization of blood and its derivatives with vitamins

Country Status (7)

Country Link
US (1) US5011695A (enrdf_load_stackoverflow)
EP (1) EP0330047B1 (enrdf_load_stackoverflow)
JP (1) JPH025957A (enrdf_load_stackoverflow)
AT (1) ATE80803T1 (enrdf_load_stackoverflow)
DE (2) DE3805459A1 (enrdf_load_stackoverflow)
ES (1) ES2035384T3 (enrdf_load_stackoverflow)
GR (1) GR3006630T3 (enrdf_load_stackoverflow)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288605A (en) * 1992-03-02 1994-02-22 Steritech, Inc. Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5482828A (en) * 1992-03-02 1996-01-09 Steritech, Inc. Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US6251580B1 (en) 1992-03-02 2001-06-26 Lily Lin Synthetic media for blood components
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6548241B1 (en) 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
US20030215784A1 (en) * 1998-07-21 2003-11-20 Dumont Larry Joe Method and apparatus for inactivation of biological contaminants using photosensitizers
US20040001816A1 (en) * 1998-06-22 2004-01-01 Cytomedix, Inc. Enriched platelet wound healant
US20040018997A1 (en) * 1998-07-21 2004-01-29 Heather Reddy Inactivation of West Nile virus and malaria using photosensitizers
US20040081956A1 (en) * 2000-06-02 2004-04-29 Gambro, Inc. Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
EP1091735A4 (en) * 1998-06-22 2004-05-06 Cytomedix Inc IMPROVED WOUND HEALING WITH ENRICHED PLATES
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US20050112021A1 (en) * 2000-06-15 2005-05-26 Gambro, Inc. Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light
US20050282143A1 (en) * 1998-07-21 2005-12-22 Gambro, Inc. Use of visible light at wavelengths of 500 nm and higher to pathogen reduce blood and blood components
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US20070071740A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Purified amniotic membrane compositions and methods of use
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US20070098697A1 (en) * 2000-06-02 2007-05-03 Navigant Biotechnologies, Inc. Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US20080107636A1 (en) * 2000-06-02 2008-05-08 Navigant Biotechnologies, Llc Induction of and Maintenance of Nucleic Acid Damage in Pathogens Using Riboflavin and Light
US20080299538A1 (en) * 2003-02-28 2008-12-04 Caridianbct Biotechnologies, Llc Pathogen Inactivation of Whole Blood
US20090023130A1 (en) * 2003-02-28 2009-01-22 Caridianbct Biotechnologies, Llc Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light
US20130129844A1 (en) * 2010-07-28 2013-05-23 Horus Pharma Preservative-Free Composition for Topical Use Including Hyaluronic Acid
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
EP3875096A4 (en) * 2018-11-07 2022-11-09 TERUMO Kabushiki Kaisha METHOD OF PREPARING A BLOOD PRODUCT AND BLOOD PRODUCT

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3930510A1 (de) * 1989-09-13 1991-03-21 Blutspendedienst Dt Rote Kreuz Verfahren zur inaktivierung von viren in blut und blutprodukten
US5242642A (en) * 1989-11-25 1993-09-07 Seiko Epson Corporation Method of manufacturing a switch substrate
JPH03219509A (ja) * 1989-11-25 1991-09-26 Seiko Epson Corp スイッチ基板及びスイッチ基板製造方法
AR001654A1 (es) * 1995-04-19 1997-11-26 Univ East Carolina Método para la descontaminacion microbiana de plaquetas sanguineas
JP4828126B2 (ja) * 2005-02-03 2011-11-30 日本メナード化粧品株式会社 抗菌剤

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1556120A (en) * 1925-10-06 Method of sterilizing proteins or other colloidal material
US4179338A (en) * 1977-09-19 1979-12-18 Gordon Maurice R Microbiological medium suitable for sterilization by ionizing radiation
US4446134A (en) * 1981-10-28 1984-05-01 The Green Cross Corporation Process for heat treatment of aqueous solution containing human blood coagulation factor VIII
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
EP0127605A2 (de) * 1983-05-31 1984-12-05 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Herstellung von Präparationen aus menschlichem Blutplasma
US4610814A (en) * 1983-06-03 1986-09-09 Kiskunhalasi Allami Gazdasag Process for the preparation of protein concentrates and nutriments by processing animal blood
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
US4845074A (en) * 1982-05-13 1989-07-04 Cedars Sinai Medical Center Heat treatment of Factor VIII

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1556120A (en) * 1925-10-06 Method of sterilizing proteins or other colloidal material
US4179338A (en) * 1977-09-19 1979-12-18 Gordon Maurice R Microbiological medium suitable for sterilization by ionizing radiation
US4446134A (en) * 1981-10-28 1984-05-01 The Green Cross Corporation Process for heat treatment of aqueous solution containing human blood coagulation factor VIII
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4845074A (en) * 1982-05-13 1989-07-04 Cedars Sinai Medical Center Heat treatment of Factor VIII
EP0127605A2 (de) * 1983-05-31 1984-12-05 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Herstellung von Präparationen aus menschlichem Blutplasma
US4610814A (en) * 1983-06-03 1986-09-09 Kiskunhalasi Allami Gazdasag Process for the preparation of protein concentrates and nutriments by processing animal blood
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Murata et al., Chem. Abstracts, vol. 102 (1985) 218208v. *
Murata et al., Chem. Abstracts, vol. 103 (1985) 51128a. *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5288605A (en) * 1992-03-02 1994-02-22 Steritech, Inc. Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen
US20030194806A1 (en) * 1992-03-02 2003-10-16 Lily Lin Synthetic media for blood components
US5482828A (en) * 1992-03-02 1996-01-09 Steritech, Inc. Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US6251580B1 (en) 1992-03-02 2001-06-26 Lily Lin Synthetic media for blood components
US6866992B2 (en) 1992-03-02 2005-03-15 Baxter International Inc. Synthetic platelet storage media formulation
US6566046B2 (en) 1992-03-02 2003-05-20 Baxter International Inc. Synthetic media for blood components
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US20040001816A1 (en) * 1998-06-22 2004-01-01 Cytomedix, Inc. Enriched platelet wound healant
EP1091735A4 (en) * 1998-06-22 2004-05-06 Cytomedix Inc IMPROVED WOUND HEALING WITH ENRICHED PLATES
US7112342B2 (en) 1998-06-22 2006-09-26 Cytomedix, Inc. Enriched platelet wound healant
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US20030215784A1 (en) * 1998-07-21 2003-11-20 Dumont Larry Joe Method and apparatus for inactivation of biological contaminants using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US20040018997A1 (en) * 1998-07-21 2004-01-29 Heather Reddy Inactivation of West Nile virus and malaria using photosensitizers
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US20050282143A1 (en) * 1998-07-21 2005-12-22 Gambro, Inc. Use of visible light at wavelengths of 500 nm and higher to pathogen reduce blood and blood components
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6828323B2 (en) 1999-10-19 2004-12-07 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US20080107636A1 (en) * 2000-06-02 2008-05-08 Navigant Biotechnologies, Llc Induction of and Maintenance of Nucleic Acid Damage in Pathogens Using Riboflavin and Light
US7892535B2 (en) 2000-06-02 2011-02-22 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US7901673B2 (en) 2000-06-02 2011-03-08 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US20040081956A1 (en) * 2000-06-02 2004-04-29 Gambro, Inc. Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US20070098697A1 (en) * 2000-06-02 2007-05-03 Navigant Biotechnologies, Inc. Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US20100080781A1 (en) * 2000-06-02 2010-04-01 Caridianbct Biotechnologies, Llc Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US20050112021A1 (en) * 2000-06-15 2005-05-26 Gambro, Inc. Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6548241B1 (en) 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
US20030186213A1 (en) * 2000-11-28 2003-10-02 Mcburney Laura Storage solution containing photosensitizer for inactivation of biological contaminants
US20040023201A9 (en) * 2000-11-28 2004-02-05 Mcburney Laura Storage solution containing photosensitizer for inactivation of biological contaminants
US20080299538A1 (en) * 2003-02-28 2008-12-04 Caridianbct Biotechnologies, Llc Pathogen Inactivation of Whole Blood
US20090023130A1 (en) * 2003-02-28 2009-01-22 Caridianbct Biotechnologies, Llc Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light
US20070071740A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Purified amniotic membrane compositions and methods of use
US20130129844A1 (en) * 2010-07-28 2013-05-23 Horus Pharma Preservative-Free Composition for Topical Use Including Hyaluronic Acid
US10231990B2 (en) * 2010-07-28 2019-03-19 Horus Pharma Preservative-free composition for topical use including hyaluronic acid
EP3875096A4 (en) * 2018-11-07 2022-11-09 TERUMO Kabushiki Kaisha METHOD OF PREPARING A BLOOD PRODUCT AND BLOOD PRODUCT

Also Published As

Publication number Publication date
ATE80803T1 (de) 1992-10-15
DE3805459A1 (de) 1989-08-31
DE58902313D1 (de) 1992-10-29
ES2035384T3 (es) 1993-04-16
JPH025957A (ja) 1990-01-10
EP0330047B1 (de) 1992-09-23
GR3006630T3 (enrdf_load_stackoverflow) 1993-06-30
EP0330047A2 (de) 1989-08-30
EP0330047A3 (en) 1990-12-19

Similar Documents

Publication Publication Date Title
US5011695A (en) Sterilization of blood and its derivatives with vitamins
CA1223203A (en) Protein compositions substantially free from infectious agents
DE69434445T2 (de) Verfahren zur sterilisation biologischer zusammensetzungen und das dabei erhaltene produkt
US4946648A (en) Method of sterilizing plasma or plasma fractions
CA1207229A (en) Sterilized plasma and plasma derivatives and process therefor
US4727027A (en) Photochemical decontamination treatment of whole blood or blood components
US5281392A (en) Method for disinfecting red blood cells, blood products, and corneas
US5639730A (en) Method of producing a virus-safe biological preparation
HU213470B (en) Process for producing virus-inactivated blood-product
JPS6051116A (ja) 脂質含有ウイルスを含まない蛋白質含有組成物及びその製造方法
KR100383467B1 (ko) 아크리딘또는아크리딘유도체보조하의바이러스의불활성화방법
RU2112522C1 (ru) Состав для стабилизации плазмы крови, способ пастеризации плазмы и использование стабилизированной плазмы в терапии
KR100261360B1 (ko) 바이러스-유리된 트롬빈 농축물 제조방법
EP0292003B1 (en) Stabilzation of biological and pharmaceutical products during inactivation of viral and bacterial contaminants
CA2822229C (en) Caprylate viral deactivation
EP1415669A1 (en) Process for sterilization of protein containing biological compositions
JP4629831B2 (ja) ウィルスの不活化方法
EP0686694B1 (en) Use of azoles as virucidal agents in solutions of biologically active proteins
CA2228031A1 (en) Doubly virus-inactivated human blood plasma, blood plasma derivatives produced therefrom and method for their production
DK175644B1 (da) Fremgangsmåde til stabilisering af biologiske og farmaceutiske midler under inaktivering af virale og bakterielle kontaminanter
EP1609485A1 (en) Method for the inactivation of viral components of protein-containing biological compositions
EP1400248A1 (en) Process for sterilization of protein containing biological compositions
HK1194679B (en) Caprylate viral deactivation
HU217083B (hu) Vírusinaktivált vérkészítmény
JPS58205495A (ja) 胎盤性アスパラギン酸アミノペプチダ−ゼの加熱安定化法

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOTEST PHARMA GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:DICHTELMULLER, HERBERT;STEPHAN, WOLFGANG;REEL/FRAME:005045/0496

Effective date: 19890208

CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19950503

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362